Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Product and Geography - Forecast and Analysis 2021-2025

The attention deficit hyperactivity disorder (ADHD) drugs market share is expected to increase by USD 9.61 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 9.06%.

This attention deficit hyperactivity disorder drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers attention deficit hyperactivity disorder drugs market segmentation by product (stimulants and non-stimulants) and geography (North America, Europe, Asia, and ROW). The attention deficit hyperactivity disorder drugs market report also offers information on several market vendors, including Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc. among others.

What will the Attention Deficit Hyperactivity Disorder Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Attention Deficit Hyperactivity Disorder Drugs Market Size for the Forecast Period and Other Important Statistics

Attention Deficit Hyperactivity Disorder Drugs Market: Key Drivers and Challenges

The rising government support is notably driving the ADHD drugs market growth, although factors such as lack of proper diagnostic criteria for ADHD in adults may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the attention deficit hyperactivity disorder drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Attention Deficit Hyperactivity Disorder Drugs Market Driver

The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote awareness of the disease and to fund drug development in the area of mental health therapeutics. For instance, the US Department of Health and Human Services (HHS) donated $3,454 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) to address the needs of people with mental illnesses. Similarly, the National Health Service (NHS) England has set up a plan to help people with mental illness. The NHS England spent approximately $16 billion on mental health in 2018-2020. Additionally, the CDC funds the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period. 

Key Attention Deficit Hyperactivity Disorder Drugs Market Challenge

Physicians currently face a daunting challenge in terms of the diagnosis of ADHD in adults. The current diagnostic criteria for ADHD include the presence of 18 symptoms, which are broadly categorized under three main symptoms, namely, inattention, impulsivity, and hyperactivity. Clinical studies have revealed that these symptoms play a steering role in defining ADHD in both children and adults of any age. However, to validate these symptoms in adults, physicians need to perform a longitudinal study of their childhood, family history, treatment response, and neuropsychological analysis. The use of screening tools and informed applications such as DSM-IV, brochures, and the cultivation of consultation and referral services can help physicians significantly augment the diagnosis and treatment of adults with ADHD. However, until a proper guideline is laid for the diagnosis of ADHD in adults, the consumption of ADHD drugs will be limited, which will hinder the growth of the market, both in terms of volume and value, during the forecast period.

This attention deficit hyperactivity disorder drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Attention Deficit Hyperactivity Disorder Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Aurobindo Pharma Ltd.
• Aytu BioPharma Inc.
• Eli Lilly and Co.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson Inc.
• Novartis AG
• Purdue Pharma LP
• SHIONOGI Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Tris Pharma Inc.

This statistical study of the attention deficit hyperactivity disorder drugs market encompasses successful business strategies deployed by the key vendors. The ADHD drugs market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The attention deficit hyperactivity disorder drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Attention Deficit Hyperactivity Disorder Drugs Market?